Stocks News

LAST PRICE
131.4800
TODAY'S CHANGE (%)
Trending Down-5.6900 (-4.1481%)

Bid / Lots
52.6900/ 2
Ask / Lots
133.0000/ 1
Open / Previous Close
136.8700 / 137.1700
Day Range
Low 131.2500
High 138.3800
52 Week Range
Low 85.0801
High 161.0000
Volume
238,417
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Jun 5, 2024
- European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading, from 11:10AM ET on Wednesday Jun 05, 2024 by MT Newswires
  11:10AM ET on Wednesday Jun 05, 2024 by MT Newswires
  Companies Mentioned: AVDL, LYG, TRIB, NGG, TRVG, AMRN, OPRA, GNFT, MREO, BNTX, CALT, MTLS, ASND, CLLS, ADAP, BDRX
  11:10 AM EDT, 06/05/2024 (MT Newswires) -- European equities traded in the US as American depositary receipts were higher Wednesday morning, rising 0.93% to 1,436.34 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led b...
Jun 4, 2024
- Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference, from 4:01PM ET on Tuesday Jun 04, 2024 by GlobeNewswire
  4:01PM ET on Tuesday Jun 04, 2024 by GlobeNewswire
  Companies Mentioned: ASND
- Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference, from 4:01PM ET on Tuesday Jun 04, 2024 by Dow Jones
  4:01PM ET on Tuesday Jun 04, 2024 by Dow Jones
  Companies Mentioned: ASND
  
  Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
  
  COPENHAGEN, Denmark, June 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024, at 8:00 a.m. ET in Miami, Florida.
Jun 3, 2024
- Ascendis Pharma Reports 45% Clinical Response in TransCon IL-2 Phase 1/2 Trial, from 4:34PM ET on Monday Jun 03, 2024 by MT Newswires
  4:34PM ET on Monday Jun 03, 2024 by MT Newswires
  Companies Mentioned: ASND
  04:34 PM EDT, 06/03/2024 (MT Newswires) -- Ascendis Pharma (ASND) said Monday that 45% of patients with locally advanced or metastatic solid tumors getting TransCon IL-2 every three weeks in the phase 1/2 clinical trial showed clinical response. The...
- Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024, from 4:01PM ET on Monday Jun 03, 2024 by GlobeNewswire
  4:01PM ET on Monday Jun 03, 2024 by GlobeNewswire
  Companies Mentioned: ASND

Yesterday
- Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference, from 16 hours ago by GlobeNewswire
  16 hours ago by GlobeNewswire
  Companies Mentioned: ITCI
Jun 9, 2024
- Currently, The Schall Law Firm is Actively Probing Possible Securities Law Breaches for the Benefit of Investors of Blueprint Medicines Corporation (NASDAQ:BPMC), from 11:05AM ET on Sunday Jun 09, 2024 by Accesswire
  11:05AM ET on Sunday Jun 09, 2024 by Accesswire
  Companies Mentioned: BPMC
Jun 8, 2024
- Presently, The Schall Law Firm is Conducting Investigations into Potential Securities Law Violations for the Advantage of Investors of Blueprint Medicines Corporation (NASDAQ:BPMC), from 11:02AM ET on Saturday Jun 08, 2024 by Accesswire
  11:02AM ET on Saturday Jun 08, 2024 by Accesswire
  Companies Mentioned: BPMC
Jun 7, 2024
- Blueprint Medicines Insider Sold Shares Worth $420,520, According to a Recent SEC Filing, from 4:07PM ET on Friday Jun 07, 2024 by MT Newswires
  4:07PM ET on Friday Jun 07, 2024 by MT Newswires
  Companies Mentioned: BPMC
- Currently, The Schall Law Firm is Undertaking Probes into Possible Securities Law Breaches for the Benefit of Investors of Blueprint Medicines Corporation (NASDAQ:BPMC), from 12:47PM ET on Friday Jun 07, 2024 by Accesswire
  12:47PM ET on Friday Jun 07, 2024 by Accesswire
  Companies Mentioned: BPMC
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4), from 8:00AM ET on Friday Jun 07, 2024 by PR Newswire
  8:00AM ET on Friday Jun 07, 2024 by PR Newswire
  Companies Mentioned: INSM
- --Mizuho Adjusts Price Target on Insmed to $82 From $36, Maintains Buy Rating, from 5:47AM ET on Friday Jun 07, 2024 by MT Newswires
  5:47AM ET on Friday Jun 07, 2024 by MT Newswires
  Companies Mentioned: INSM
Jun 6, 2024
- At Present, The Schall Law Firm Is Conducting Investigations Into Potential Violations Of Securities Laws For The Investors Of Blueprint Medicines Corporation (NASDAQ:BPMC), from 11:46AM ET on Thursday Jun 06, 2024 by Accesswire
  11:46AM ET on Thursday Jun 06, 2024 by Accesswire
  Companies Mentioned: BPMC
Jun 5, 2024
- Insmed Insider Sold Shares Worth $3,043,150, According to a Recent SEC Filing, from 4:27PM ET on Wednesday Jun 05, 2024 by MT Newswires
  4:27PM ET on Wednesday Jun 05, 2024 by MT Newswires
  Companies Mentioned: INSM
- Blueprint Medicines Insider Sold Shares Worth $259,263, According to a Recent SEC Filing, from 4:11PM ET on Wednesday Jun 05, 2024 by MT Newswires
  4:11PM ET on Wednesday Jun 05, 2024 by MT Newswires
  Companies Mentioned: BPMC

Ascendis Pharma A/S
NASDAQ:ASNDUnited States

Search Criteria

Jun 5, 2024

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading, from 11:10AM ET on Wednesday Jun 05, 2024 by MT Newswires

Jun 4, 2024

Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference, from 4:01PM ET on Tuesday Jun 04, 2024 by GlobeNewswire

Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference, from 4:01PM ET on Tuesday Jun 04, 2024 by Dow Jones

Jun 3, 2024

Ascendis Pharma Reports 45% Clinical Response in TransCon IL-2 Phase 1/2 Trial, from 4:34PM ET on Monday Jun 03, 2024 by MT Newswires

Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024, from 4:01PM ET on Monday Jun 03, 2024 by GlobeNewswire

Peers Headlines

Yesterday

Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference, from 16 hours ago by GlobeNewswire

Jun 9, 2024

Currently, The Schall Law Firm is Actively Probing Possible Securities Law Breaches for the Benefit of Investors of Blueprint Medicines Corporation (NASDAQ:BPMC), from 11:05AM ET on Sunday Jun 09, 2024 by Accesswire

Jun 8, 2024

Presently, The Schall Law Firm is Conducting Investigations into Potential Securities Law Violations for the Advantage of Investors of Blueprint Medicines Corporation (NASDAQ:BPMC), from 11:02AM ET on Saturday Jun 08, 2024 by Accesswire

Jun 7, 2024

Blueprint Medicines Insider Sold Shares Worth $420,520, According to a Recent SEC Filing, from 4:07PM ET on Friday Jun 07, 2024 by MT Newswires

Currently, The Schall Law Firm is Undertaking Probes into Possible Securities Law Breaches for the Benefit of Investors of Blueprint Medicines Corporation (NASDAQ:BPMC), from 12:47PM ET on Friday Jun 07, 2024 by Accesswire

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4), from 8:00AM ET on Friday Jun 07, 2024 by PR Newswire

--Mizuho Adjusts Price Target on Insmed to $82 From $36, Maintains Buy Rating, from 5:47AM ET on Friday Jun 07, 2024 by MT Newswires

Jun 6, 2024

At Present, The Schall Law Firm Is Conducting Investigations Into Potential Violations Of Securities Laws For The Investors Of Blueprint Medicines Corporation (NASDAQ:BPMC), from 11:46AM ET on Thursday Jun 06, 2024 by Accesswire

Jun 5, 2024

Insmed Insider Sold Shares Worth $3,043,150, According to a Recent SEC Filing, from 4:27PM ET on Wednesday Jun 05, 2024 by MT Newswires

Blueprint Medicines Insider Sold Shares Worth $259,263, According to a Recent SEC Filing, from 4:11PM ET on Wednesday Jun 05, 2024 by MT Newswires